Led by Riccardo Corrias, an R&D Software Engineer at FINCONS Group , the webinar detailed how this secure digital platform is revolutionizing how we collect, organize, and utilize patient data to support better research and more precise care.

Why the Atlas? Solving the Diagnostic Puzzle

Diagnosis in NMDs is notoriously difficult because hundreds of different rare diseases often present with nearly identical symptoms like weakness, fatigue, or pain. However, the underlying causes—whether in the genes, nerves, or muscles—are vastly different.

The CoMPaSS-NMD Atlas addresses this by bringing together four critical pillars of patient information in one secure place:

  • Clinical Data: Detailed records of muscle strength, symptoms, and how the disease affects daily life.

  • MRI Scans: Images that reveal patterns of muscle involvement invisible to the naked eye.

  • Histological Data: Microscopic digital images of muscle biopsies showing fiber changes or scarring.

  • Genetic Information: Results from DNA tests that help connect specific symptoms to genetic variants.

By centralizing this data, the Atlas helps researchers and doctors see patterns across large groups of patients that would be impossible to identify in a single individual.

Data Protection: Security by Design

A primary focus of the platform is the absolute protection of patient privacy. The Atlas is not a public website; it is a specialized research tool. Key security features include:

  • Pseudonymisation: The Atlas does not store names, addresses, or dates of birth. Instead, it uses a unique CoMPaSS code.

  • Local Control: Only the local clinical center holds the “key” to link a code back to a specific person.

  • Restricted Access: Access is strictly limited to authorized members of the CoMPaSS-NMD project, with different permissions based on the user’s role.

A Living Platform: Current Status and Next Steps

The CoMPaSS-NMD Atlas is already operational, with clinical centers currently uploading prospective data. It serves as a centralized, user-friendly catalogue where researchers can use high-quality metadata and low-resolution imaging previews to identify relevant information for further study.

Looking ahead, the platform is set to become even more capable. Future developments include:

  • Advanced HPO-Filtering: Integrating the Human Phenotype Ontology (HPO) to allow for more powerful searches and suggested diagnostic directions.

  • Machine Learning Integration: Incorporating clustering models to automatically group patients with similar characteristics, aiding in more personalized therapy development.

  • Enhanced Data Quality: New tools will allow clinical centers to review and correct their data directly, ensuring the highest reliability for research.

As part of the broader Neuromuscular Genome Atlas (NMDGA) initiative, this platform represents a landmark step toward a more precise definition of neuromuscular diseases and a future where diagnosis is faster, more accurate, and more personalized.

Interested in learning more? You can reach out to us at comm@compass-nmd.eu